Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 proof-of-concept study ERY001 in the patients with triple negative breast cancer

Trial Profile

Phase 2 proof-of-concept study ERY001 in the patients with triple negative breast cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2018

At a glance

  • Drugs ERY-ASP (Primary)
  • Indications Breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 15 Nov 2018 According to an ERYtech Pharma media release, the company has a red blood cell supply and research partnership with New York Blood Center (NYBC) for this and other trial (see profile 285388). This trial is expected begin enrollment in the United States early in 2019.
    • 10 Sep 2018 According to an ERYtech Pharma media release, first patient is expected to enroll in Q4 2018.
    • 15 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top